Dr Mesa discusses the data that led to the FDA approval of pacritinib, toxicities clinicians should be aware of when prescribing the JAK inhibitor, and the next steps for pacritinib in the space.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
